High prevalence of vitamin D deficiency in women with breast cancer: The first Chilean study

Acevedo, Francisco; Perez, Victoria; Pérez-Sepúlveda, Alejandra; Florenzano, Pablo; Artigas, Rocío; Medina, Lidia; Sánchez, César

doi:10.1016/j.breast.2016.06.022

Cited by 16 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there is still no consensus on optimal serum 25OH vitamin D levels, levels below 20 ng per millilitre (ng/mL) have been established as a deficiency, and levels above 150 ng/mL as toxic [18]. All levels between these two extremes are considered normal, but levels between 30 and 60 ng/mL are considered optimal.…”

Section: Pathophysiology Of Vitamin D and Its Role In Breast Cancermentioning

confidence: 99%

Vitamin D: And its role in breast cancer

Yagüe

Cuadrado-Cenzual

Ciudad-Cabañas

et al. 2018

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Vitamin D is a fat soluble vitamin that plays a role in calcium and phosphorus homeostasis. Recently, extensive research on its extraskeletal actions has linked vitamin D deficiency to an increased risk of infection, diabetes mellitus types 1 and 2, cardiovascular disease, obesity, asthma, inflammatory bowel disease, colon, breast, prostate and ovarian cancer and some neurological diseases. There are various mechanisms by which vitamin D influences the natural history of cancer. These include the role of vitamin D in the induction of apoptosis, stimulation of cell differentiation, anti-inflammatory and antiproliferative effects and inhibition of angiogenesis, invasion and metastasis. The aim of this review is to clarify the true role of vitamin D in the onset of breast cancer and evolution of the disease after treatment. A further aim is to suggest new research directions to identify indications and requirements for vitamin D supplementation in patients with breast cancer.

show abstract

Section: Pathophysiology Of Vitamin D and Its Role In Breast Cancermentioning

confidence: 99%

Vitamin D: And its role in breast cancer

Yagüe

Cuadrado-Cenzual

Ciudad-Cabañas

et al. 2018

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

show abstract

“…Considering population studies from other countries, Acevedo (2016) reported that 98/105 (93.3%) Chilean women with breast cancer and 88/93 (94.6%) of cases with Luminal A/B tumors had vitamin D insufficiency/ deficiency (≤29.9 ng / mL). Further, 51/53 (96%) of histological grade 3 tumors showed levels of vitamin D in the same range of insufficiency.…”

Section: Discussionmentioning

confidence: 99%

“…More recently, low levels of circulating vitamin D in the population have been identified as a risk factor for tumors in general, especially breast cancer, but this association of risk is still controversial (Eliassen et al, 2016;Acevedo et al, 2016). On the other hand, high levels of vitamin D have contributed to better prognosis and overall survival for breast cancer cases (Yao et al, 2017;Villaseñor et al, 2013), and have even reduced the ability of metastasis in in vitro and in vivo assays (Wilmanski et al, 2016;Williams et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Low Levels of Vitamin D in a Cohort of Women with Impalpable Breast Lesions from Rio de Janeiro/Brazil

Delmonico

Costa²,

Azevedo

et al. 2018

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background:Low levels of vitamin D have been described as a risk factor for the development of breast cancer. The aim of this study was to evaluate the serum levels of vitamin D (25OHD) in patients with impalpable breast lesions comparing with a control group.Methods:Vitamin D quantification (25OHD) was assessed in the plasma of 65 patients with impalpable breast lesions and from 20 health controls using a chemiluminescent microparticle immunoassay. Pearson’s chi-square test and nonparametric t-Student were used to evaluate statistical significance between the clinical variables and the means of quantification of vitamin D. The receiver operating characteristic (ROC) curve was used to evaluate the correlation between age and vitamin sufficiency for the cases and the controls.Results:The prevalence of vitamin D deficiency and/or insufficiency in women with malignant lesions was 84% and 60% for the control group. Using the chi-square or Fisher’s exact test, the relationship between vitamin D levels and age presented significant association only for the control group (P=0.002). Using ROC curve, the plot area (0.778) for the control group defined a cut-off value of 45 years to age, with specificity and sensitivity of 60% and 50%, respectively. Thus, the odds ratio for vitamin D insufficiency in women over 45 years was 1.37 (P=0.011). For the case group, clinical characteristics, histological grade, and lymph node involvement did not show any significant association.Conclusion:The prevalence of vitamin D deficiency/insufficiency is high in women with impalpable breast lesions, as well as in the control group, even in a tropical city. According to the results the age advancement may be involved with the decrease in vitamin D levels in plasma, but there was no statistical association between low levels of Vitamin D and breast cancer.

show abstract

“…Individuals at risk for bone loss are recommended to consume 1200 to 1500 mg of calcium and 400 to 600 IU of vitamin D per day; however, there are no established guidelines for calcium and vitamin D in patients with cancer . Studies have shown that 70% to 97.5% of patients with cancer are vitamin D deficient . Calcium levels in patients with cancer vary.…”

Section: Exercise and Nutritional Interventionsmentioning

confidence: 99%

Cancer‐ and Chemotherapy‐Induced Musculoskeletal Degradation

et al. 2019

View full text Add to dashboard Cite

Mobility in advanced cancer patients is a major health care concern and is often lost in advanced metastatic cancers. Erosion of mobility is a major component in determining quality of life but also starts a process of loss of muscle and bone mass that further devastates patients. In addition, treatment options become limited in these advanced cancer patients. Loss of bone and muscle occurs concomitantly. Advanced cancers that are metastatic to bone often lead to bone loss (osteolytic lesions) but may also lead to abnormal deposition of new bone (osteoblastic lesions). However, in both cases there is a disruption to normal bone remodeling and radiologic evidence of bone loss. Many antitumor therapies can also lead to loss of bone in cancer survivors. Bone loss releases cytokines (TGFβ) stored in the mineralized matrix that can act on skeletal muscle and lead to weakness. Likewise, loss of skeletal muscle mass leads to reduced bone mass and quality via mechanical and endocrine signals. Collectively these interactions are termed bone‐muscle cross‐talk, which has garnered much attention recently as a prime target for musculoskeletal health. Pharmacological approaches as well as nutrition and exercise can improve muscle and bone but have fallen short in the context of advanced cancers and cachexia. This review highlights our current knowledge of these interventions and discusses the difficulties in treating severe musculoskeletal deficits with the emphasis on improving not only bone mass and muscle size but also functional outcomes. © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.

show abstract

High prevalence of vitamin D deficiency in women with breast cancer: The first Chilean study

Cited by 16 publications

References 38 publications

Vitamin D: And its role in breast cancer

Vitamin D: And its role in breast cancer

Low Levels of Vitamin D in a Cohort of Women with Impalpable Breast Lesions from Rio de Janeiro/Brazil

Cancer‐ and Chemotherapy‐Induced Musculoskeletal Degradation

Contact Info

Product

Resources

About